Ocular Therapeutix randomizes more than 300 patients in SOL-1 Phase 3 trial for OTX-TKI

News
Article

The trial is expected to close randomization in early December 2024.

Doctor showing patient a tablet Image credit: AdobeStock/bongkarn

Image credit: AdobeStock/bongkarn

More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024. This is the first registrational clinical trial of OTX-TKI in wet age-related macular degeneration (wet AMD) and is on track to report topline data in the fourth quarter of 2025.1

Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix shared his thoughts on this milestone in the company’s press release1, saying, “SOL-1 reaching target randomization in 2024 is a landmark event for Ocular. SOL-1 is an important trial for patients and the retina community as there is an urgent unmet need for durable therapies capable of maintaining visual acuity and improving long-term outcomes. Today’s milestone brings us one step closer to our goal of delivering the first wet AMD therapy potentially capable of being dosed as infrequently as every six to nine months. Achieving this progress reflects our positive engagement with the retina community, the dedication of our clinical sites, and the demand for a durable treatment option for wet AMD.”

Dugel continued, “Thanks to the excellent momentum from SOL-1, we recently ‘flipped the switch’, allowing active clinical sites to enroll patients directly into our second registrational study in wet AMD, SOL-R, further accelerating its pace of enrollment. Thanks to the palpable enthusiasm from the investigators and study site teams, we continue to make excellent progress with the enrollment of SOL-R, with a steady focus on our overall mission of improving vision for patients.”1

The momentum of SOL-1 has benefitted Ocular’s second registrational clinical trial, the SOL-R repeat dosing trial. Earlier in Q4 of 2024, Ocular allowed investigators to enroll their patients directly into SOL-R. Previously, patients were required to be a SOL-1 loading or randomization failure. The SOL-R trial has seen an acceleration in recruitment and expected to be amplified by subjects enrolled but not ultimately randomized into SOL-1 because randomization targets are met. Ocular continues to activate additional clinical trial sites worldwide to further the speed of SOL-R enrollment.1

About the SOL-1 and SOL-R studies

Ocular’s wet AMD registrational program for OTX-TKI is comprised of 2 complementary studies, designed with the intent of de-risking clinical outcomes, aligning with regulatory standards, enhancing each other’s enrollment, and providing a broad evaluation of durability, repeatability, and flexibility. SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug Administration (FDA). In a written Type C response, the FDA agreed that the SOL-R non-inferiority study should be appropriate as a second adequate and well-controlled study to support a potential New Drug Application (NDA).1

Reference:
  1. Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1. Ocular Therapeutix, Inc. December 2, 2024. December 3, 2024. https://www.globenewswire.com/news-release/2024/12/02/2989687/0/en/Ocular-Therapeutix-Announces-More-Than-300-Subjects-Randomized-in-SOL-1.html
Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.